AbbVie has plenty of cost-cutting room if Humira sales hit the skids: analyst

Some industry watchers foresee biosimilars gutting Humira sales not too far into the future, though maker AbbVie ($ABBV) disagrees. If that scenario does play out, though? The Illinois pharma has room to pare down its marketing expenses, according to one analyst. Report